Press Releases Items Per Page 102550 Year None20222021202020192018201720162015201420132012201120102007 05.11.22 Syndax Announces Participation at Citi's Biopharma Virtual Co-Panel Day 05.09.22 Syndax Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Business Update 05.02.22 Syndax to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 9, 2022 03.04.22 Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 03.01.22 Syndax Pharmaceuticals Reports Fourth Quarter 2021 Financial Results and Provides Clinical and Business Update 03.01.22 Syndax Pharmaceuticals Announces Appointment of Kate Madigan, M.D., as Chief Medical Officer 02.28.22 Syndax Announces Participation at Two Upcoming Investor Conferences 02.22.22 Syndax to Announce Fourth Quarter and Year-end 2021 Financial Results and Host Conference Call and Webcast on March 1, 2022 02.03.22 Syndax Pharmaceuticals Announces Transition of Michael A. Metzger to Chief Executive Officer; Briggs W. Morrison, M.D., to Assume Role of President, Head of Research & Development 01.20.22 Syndax Announces Presentation at B. Riley Securities' 2022 Oncology Conference 01.07.22 Syndax Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference 12.22.21 Syndax Announces Orphan Drug Designation Granted to SNDX-5613 by European Commission for the Treatment of Acute Myeloid Leukemia Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
05.09.22 Syndax Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Business Update
05.02.22 Syndax to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 9, 2022
03.01.22 Syndax Pharmaceuticals Reports Fourth Quarter 2021 Financial Results and Provides Clinical and Business Update
03.01.22 Syndax Pharmaceuticals Announces Appointment of Kate Madigan, M.D., as Chief Medical Officer
02.22.22 Syndax to Announce Fourth Quarter and Year-end 2021 Financial Results and Host Conference Call and Webcast on March 1, 2022
02.03.22 Syndax Pharmaceuticals Announces Transition of Michael A. Metzger to Chief Executive Officer; Briggs W. Morrison, M.D., to Assume Role of President, Head of Research & Development
12.22.21 Syndax Announces Orphan Drug Designation Granted to SNDX-5613 by European Commission for the Treatment of Acute Myeloid Leukemia
